S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
Free Trial
NASDAQ:SURF

Surface Oncology (SURF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free SURF Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.01
▼
$1.09
50-Day Range
$0.88
▼
$1.08
52-Week Range
$0.56
▼
$1.43
Volume
1.51 million shs
Average Volume
430,375 shs
Market Capitalization
$65.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
SURF stock logo

About Surface Oncology Stock (NASDAQ:SURF)

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.

SURF Stock News Headlines

April 18, 2024 | msn.com
Mill Creek clinic can now cure some skin cancers without surgery
April 18, 2024 | finance.yahoo.com
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
April 19, 2024 | Paradigm Press (Ad)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
April 17, 2024 | msn.com
Gritstone bio (GRTS) Price Target Decreased by 37.04% to 5.78
April 17, 2024 | msn.com
Targeted therapies outperform hundreds of other drugs in 'priming' lung cancer cells for destruction
April 16, 2024 | finance.yahoo.com
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
April 11, 2024 | finance.yahoo.com
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
April 10, 2024 | msn.com
Look Up and See the Future
April 19, 2024 | Paradigm Press (Ad)
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
April 9, 2024 | finance.yahoo.com
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
April 9, 2024 | msn.com
Extracellular cell matrix stiffness may induce drug resistance of breast cancer cells
April 9, 2024 | msn.com
Targeted Therapy Revolution: For People With Cancers That Have A Special Factor Called HER2, The Drug Enhertu Is Now Approved Across Tumor Types- What To Ask Your Doctor
April 9, 2024 | finance.yahoo.com
Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines
April 8, 2024 | businesswire.com
Orthobond Secures De Novo Classification Grant for First-in-Class Antibacterial Surface Treatment Applied to a Spinal Device
April 6, 2024 | finance.yahoo.com
Tempus Introduces Workspaces into its Lens Data Analytics Platform
April 5, 2024 | finance.yahoo.com
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 4, 2024 | msn.com
Is THIS what's causing mystery rise in colon cancers among young people? New research points to bacteria in the gut linked to processed food and not eating enough fiber
April 4, 2024 | msn.com
How is Metastatic Breast Cancer Treated?
April 3, 2024 | benzinga.com
Anthony A.. Florence Jr's Net Worth
April 2, 2024 | msn.com
Investigators develop novel treatment for T-cell leukemias and lymphomas
April 2, 2024 | msn.com
Using cryo-shocked tumor cells to fight lung cancer
April 1, 2024 | msn.com
Kyverna reports first use of KYV-101 for multiple sclerosis treatment
April 1, 2024 | msn.com
Advances In Early Detection Methods For Cervical Cancer
March 30, 2024 | msn.com
Brave NJ mom conquers brain surgery fears — by singing Taylor Swift songs throughout the life-saving procedure
March 30, 2024 | msn.com
New Jersey woman sings Taylor Swift hits while awake during brain surgery: 'Eras Tour' in the O.R.
March 29, 2024 | msn.com
Mulago surgeons restore knees, joints of 33 patients
March 28, 2024 | msn.com
Clinical trial: Some sarcoma patients improve with T cell immunotherapy
See More Headlines
Receive SURF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:SURF
CUSIP
N/A
CIK
1718108
Web
www.surfaceoncology.com
Phone
(617) 714-4096
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-63,590,000.00
Net Margins
N/A
Pretax Margin
-211.95%
Return on Equity
-107.81%
Return on Assets
-65.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.60
Quick Ratio
3.60

Sales & Book Value

Annual Sales
$30 million
Price / Sales
2.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.81 per share
Price / Book
1.32

Miscellaneous

Outstanding Shares
60,824,000
Free Float
53,525,000
Market Cap
$65.08 million
Optionable
Not Optionable
Beta
1.75
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

SURF Stock Analysis - Frequently Asked Questions

Should I buy or sell Surface Oncology stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SURF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SURF, but not buy additional shares or sell existing shares.
View SURF analyst ratings or view top-rated stocks.

How were Surface Oncology's earnings last quarter?

Surface Oncology, Inc. (NASDAQ:SURF) announced its earnings results on Thursday, November, 4th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04. The firm earned $0.39 million during the quarter.

What is Jeff Goater's approval rating as Surface Oncology's CEO?

5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Hello Group (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA).

When did Surface Oncology IPO?

Surface Oncology (SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO.

This page (NASDAQ:SURF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
How Biden has already won 2024
Porter & Company
My biggest AI fear
Paradigm Press